众所周知，高品质的化妆品是建立在好配方、好肤感、好功效等多个维度基础之上的，做好其中一项并 不难，难的是做好每一项。多年以来，敷尔佳始终以产品创新为核心，以研发作为第一生产力，以高标 准覆盖产品的研发端、生产端和成品端，体现品牌持续秉持"科技赋能、品质第一、功效先行"的产品理 念。 敷尔佳的产品，从源头到出厂都需要经过四性测试，包括开展临床测试/功效性测试、安全性评价、以 及在不同环境条件下，考察产品稳定性，包材兼容性测试。与此同时，产品还要通过十道安全把关，最 终才能送到消费者手中，充分保证了产品的高品质。具体来看，在研发期，产品需要进行国标基础检 测，经过多次皮肤刺激性实验、皮肤斑贴实验以及功效评价。在原料、包材采购方面，对供应商及物料 进行严格筛选，并从化妆品原料、辅料的入库到出货前，按照研发计划进行严格验收。 智能化的触角，已延伸至生产全流程。敷尔佳产品的配制设备采用全自动控制系统，通过智能人机界面 实现高效操作与全程监控，最大程度降低人为干预风险。该系统更能实现自动清洗(CIP)与在线灭菌 (SIP)等关键环节，确保生产的连续性与无菌性，严格符合GMP标准。 在国民经济水平提升、人民对美好生活需求不 ...

截至2025年8月25日收盘，国际医学股价报5.51元，较前一交易日上涨0.55%，成交额2.54亿元，换手率 2.10%。 国际医学主营业务为医疗服务，旗下医院覆盖综合医疗、专科诊疗等领域。公司近年来通过学科建设与 科研创新推动业务发展。 风险提示：市场有风险，投资需谨慎。 消息面上，国际医学于8月22日接待了天风证券等多家机构调研，公司高管介绍了2025年上半年经营情 况，包括学科建设、业务布局优化等进展。近一年来，公司累计接受235家机构315次调研。 资金方面，8月25日主力资金净流出1368.75万元，近五日累计净流出663.41万元。 ...

导读： 近日，苏州大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出11项仪器设备采购意向，预算 总额达1.05亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 苏州大学发布 11 项仪器设备采购意向，预算总额达 1 . 0 5 亿 元，涉及高通量荧光成像系统 、通感融合光网络 传输系统、超高真空拉曼/扫描探针纤维系统之超高真空拉曼系统、6 0 0MHz固体宽腔核磁共振波谱仪 等，预计采购时 间为2 0 2 5 年 8 月。 部分采购仪器： 多功能STM-AFM显微镜 多 功 能 STM-AFM 显 微 镜 （ Multifunctional Scanning Tunnel ing Microscope - Atomic Force Microscope）是一种将扫描隧道显微术（STM）与原子力显微术（AFM）集成于一体的高端纳米表征平台，能够同 时实现原子级形貌成像、电子态探测及多种功能特性分析，是研究材料表面物理、化学、电学、磁学和力学性质的核心 工具。 MALDI TOF/TOF基质辅助激光解析电 ...

8月21日晚间，莱美药业(300006)发布2025年半年报，公司实现营业收入3.77亿元，报告期内，公司持续 聚焦优势细分领域，巩固公司拳头产品卡纳琳在相关领域的优势领先地位；保持新品持续引进，加快对 已引入新品的上市转换；通过加快高质量仿创新产品研发和技术引进，扩增仿制药业务；加大自主创新 力度，推动公司健康持续发展。 （文章来源：证券时报网） 报告显示，公司构建短、中、长期三维科研创新体系，短中期内，积极引进优质项目及创新技术，筛选 符合公司发展需要的潜力标的；公司技术中心继续开展新药仿创科研工作，进一步丰富公司细分领域产 品组合，提升公司在该领域竞争力。中长期内，公司继续推进如纳米炭铁等创新技术和产品的开发工 作；推动参股公司康德赛自主研发细胞免疫疗法和其他个性化创新医疗技术等产品，旨在培育核心技术 和长期竞争力。 公司通过研发、产品与渠道拓展的协同优势，积极适应新常态新趋势。报告期内，克林霉素磷酸酯注射 液、盐酸纳洛酮注射液、注射用尼可地尔、阿奇霉素颗粒剂、注射用吗替麦考酚酯、酮咯酸氨丁三醇注 射液等品种取得批件或补充申请批件、通过一致性评价。艾司奥美拉唑镁肠溶胶囊、替米沙坦片、注射 用艾司奥美拉唑 ...

Group 1 - The latest stock price of Xianle Health is 23.49 yuan, an increase of 0.34 yuan from the previous trading day, with an opening price of 23.23 yuan, a high of 23.58 yuan, a low of 23.10 yuan, a trading volume of 24,618 hands, and a transaction amount of 0.58 billion yuan [1] - Xianle Health operates in the food and beverage industry, focusing on the research, development, production, and sales of nutritional health foods, with products including gummies, tablets, and powders, serving global nutritional health food brands [1] - Recently, the company participated as a co-organizer in the first Shantou Health Industry Innovation Development Conference and Health Product Expo, showcasing innovative solutions in maternal and child nutrition, women's health, and probiotics, and signed a strategic cooperation agreement with the Chinese Institute of Food Science and Technology to establish an innovation fund [1] Group 2 - The innovation fund will focus on supporting research and innovation in areas such as bionic enhancement and dosage form technology, as well as nutrition and health [1] - On August 11, Xianle Health saw a net inflow of 642,800 yuan in main funds, while over the past five trading days, there was a cumulative net outflow of 8.2576 million yuan [2]

Core Viewpoint - Mengniu's low-temperature Wuhan factory has been certified as the "largest single low-temperature yogurt factory in the world" by FWRC Forbes World Records, marking a significant achievement in China's dairy industry driven by innovation and new production capabilities [1][3]. Group 1: Factory Achievements - The Mengniu low-temperature Wuhan factory, which began operations in 2021, has a planned production line of 22 and a daily capacity of 1,432.16 tons [3]. - The factory's capacity was initially the largest in Asia and has now set a world record, showcasing its leadership in global production capacity [3]. - The factory's certification is a recognition of Mengniu's world-class capacity and its commitment to "Mengniu yogurt, world quality" [3]. Group 2: Technological Innovations - The factory focuses on "digital intelligence," "flexibility," "innovation," and "green" production, utilizing advanced flexible production lines designed for high efficiency and diverse product categories [3]. - A 72-hour golden supply chain has been established, supported by a transparent and traceable digital management system, ensuring efficient operations from raw materials to consumers [3]. Group 3: Research and Development - Mengniu has established nine R&D bases globally, with a 13.4% increase in R&D investment over the past three years, fostering a collaborative innovation ecosystem [5]. - The company has developed over 18,000 proprietary strains of probiotics, achieving international leadership in probiotic research and receiving multiple prestigious awards [5][6]. - Mengniu's proprietary strain PC-01 has an 88% improvement rate for digestive issues, aligning with the "Healthy China 2030" strategy [5]. Group 4: Quality Management - Mengniu has implemented a comprehensive 4Q quality management system, integrating international standards and best practices across its product lines [6]. - The low-temperature Wuhan factory has been certified as a designated production enterprise for student milk, with an annual production capacity of 94,000 tons, making it the largest single low-temperature yogurt production base for student milk in the country [7]. - A nationwide network of 35 laboratories and a significant investment in testing equipment have been established to ensure precise risk identification and quality control throughout the production process [7].

近日，国家粮食和物资储备局科学研究院召开了2025年度"粮科—发达优秀研究生"表彰会，会上，5名 由研究院和发达面粉集团联合培养的研究生被授予"粮科—发达优秀研究生"荣誉称号。 据了解，今年，发达面粉集团股份有限公司与国家粮食和物资储备局科学研究院共同设立了"粮科—发 达优秀研究生"奖学金，该奖学金的设立彰显了发达面粉集团深耕产业、反哺育人的社会担当，也体现 了发达面粉集团对人才的重视。 多年来，发达面粉集团深耕粮食加工领域，拥有多家子公司和两个科研机构，先后被国家有关部门和山 东省人民政府认定为"中国粮食加工业十强企业"、"农业产业化国家重点龙头企业"、"国家扶贫龙头企 业"、"全国农产品加工示范基地"等。 企业的科研创新离不开人才，一直以来，爱才惜才都是发达面粉集团的特色之一。创业之初，创始人徐 山元带领一个面粉小作坊历经挫折之后，逐渐意识到人才对企业发展的重要性，就确立了"专业的事交 给专业的人去做"的理念，在当时一般工人只有二三百元工资的时候，他就花几千元的高薪聘请专业的 工程技术人员。当时就连他的老父亲都特别不理解，甚至和技术人员发生不愉快，徐山元力排众议，做 通了父亲的思想工作，给技术人员赔礼道歉 ...

Core Insights - The Yangjiang Nuclear Power Plant has celebrated its sixth anniversary of full commercial operation, marking a significant project in China's nuclear power development with six units maintaining safe and stable operations since commissioning [1] - The plant has generated a cumulative power output of 413.268 billion kWh by June 2025, providing clean energy support for the Guangdong-Hong Kong-Macao Greater Bay Area [1] Group 1: Operational Achievements - Yangjiang Nuclear Power has established the first nuclear power cluster management platform in China and is the first in the world to implement a permanent improvement project for cold sources [2] - The plant achieved a power output of 50.075 billion kWh in 2024, becoming the only nuclear power station in China to exceed 50 billion kWh for two consecutive years [2] - 87.5% of the WANO (World Association of Nuclear Operators) indicators have reached advanced global levels, with continuous excellence in major repairs [2] Group 2: Environmental Impact - The Yangjiang Nuclear Power Plant has equivalently reduced standard coal consumption by nearly 12.5 million tons and cut carbon dioxide emissions by over 33.9 million tons, equivalent to afforestation of approximately 930,000 hectares [2] Group 3: Regional Development and Employment - The plant has invested over 300 million yuan in local development, creating more than 5,000 jobs and actively participating in rural revitalization and local economic initiatives [3] - Yangjiang Nuclear Power has partnered with local universities and service providers to establish the Guangdong-Western Nuclear Power Operation and Maintenance Industry College, aiming to train 1,000 nuclear operation talents within three years [3] - Over 50 interns are currently practicing at the plant, with plans to further develop a clean energy industry alliance to enhance local economic and social development [3]

Group 1 - The report by the U.S. Senate Foreign Relations Committee criticizes the protectionist policies of the Trump administration, suggesting that these actions may weaken the U.S. competitive edge against China [1][2] - The report highlights that as the U.S. reduces its international projects, China is rapidly filling the void, expanding its influence globally [2][3] - The global university rankings show an increase in the standing of Chinese universities, with Tsinghua University rising from 13th to 11th and Peking University from 31st to 25th in the latest rankings [2][3] Group 2 - The report warns that the Trump administration's policies could lead to a talent drain from the U.S., as international students may be deterred from studying in the country [3][4] - Data indicates a significant decline in the number of Chinese students in the U.S., dropping over 25% from the 2019-2020 academic year to the 2023-2024 academic year [5][9] - The U.S. government's scrutiny of Chinese researchers has led to a chilling effect, causing many to return to China or move to other countries, thereby impacting U.S. research and innovation [7][8] Group 3 - China's investment in higher education and research has been substantial, with R&D spending reaching over $780 billion, nearly matching the U.S. [12][13] - The trend indicates a structural shift in global higher education from the West to the East, with Asian universities, particularly in China, making rapid advancements [12][14] - Experts predict that if current trends continue, China may soon rival or surpass the U.S. in key areas of innovation and technology [14]

Group 1 - The core viewpoint of the articles highlights the advancements and innovations in the pharmaceutical and manufacturing sectors in Hanzhong, particularly focusing on Hanjing Pharmaceutical and Guda CNC (Hanzhong) Co., Ltd [1][2][3] - Hanjing Pharmaceutical, established in 1970, specializes in the research, production, and sales of chemical raw materials, intermediates, and pharmaceutical preparations, providing high-quality and affordable medicines to a wide market [1] - The company has developed modern production facilities equipped with self-developed drug reaction furnaces and waste treatment systems, ensuring high purity and compliance with environmental standards [1] - Hanjing Pharmaceutical has established four high-end production workshops and has a significant market presence both domestically and internationally, exporting to over 100 countries and regions [1] Group 2 - Continuous investment in research and development has been a key factor in Hanjing Pharmaceutical's achievements, with the establishment of provincial academician and expert workstations leading to significant scientific advancements [2] - Guda CNC (Hanzhong) Co., Ltd. has rapidly developed its production capabilities, launching a new assembly line for CNC machine tools within three months, with an annual R&D investment of 30 million yuan [2] - The company produces 16 types of high-end intelligent equipment, achieving breakthroughs in core components and control systems, thus enhancing the competitiveness of the domestic manufacturing sector [2][3] - The introduction of advanced CNC technology allows for significant efficiency improvements, with one CNC machine completing the work of four traditional machines in a fraction of the time [3]